^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FREQUENCY AND STIMULATION OF NPM1-SPECIFIC IMMUNE RESPONSES BY ANTI-PD1 ANTI-BODIES IN NPM1-MUTATED AML
Published date:
05/12/2021
Excerpt:
In NPM1mut AML pts 9/15 (60%) showed immune responses against all four epitopes...the immune effect in NPM1mut patients increased markedly with the epitope NPM1 and even more when anti-PD-1 was added to CFI, with a mean reduction of 47%. All 15 showed a reduction with anti-PD1, even those that did not show any reduction with the epitope NPM1 alone.
